The Allergan Textured Breast Implant litigation is not technically a class action lawsuit, but rather a Multi-District Litigation (MDL) involving over 1,400 individual personal injury claims consolidated for management in U.S. District Court in New Jersey. The litigation stems from the FDA’s July 2019 recall of Allergan’s Biocell textured breast implants, which the agency linked to a rare cancer called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Women who received these implants—used for both cosmetic and reconstructive surgery—have filed lawsuits claiming Allergan failed to adequately warn them about the cancer risk before implantation, and that the company delayed action even after health authorities identified the danger.
As of 2025, approximately 1,456 pending lawsuits remain in MDL-2921, overseen by Judge Brian Martinotti. No major global settlement has been finalized, meaning the litigation remains active with ongoing discovery, expert reports, and motion practice. The first bellwether trial—a test case designed to assess liability—is scheduled for October 2026, which will provide the first major courtroom verdict on whether Allergan is responsible for women’s injuries. For anyone who received Allergan Biocell textured implants and has been diagnosed with BIA-ALCL or other related conditions, understanding the current status of this litigation is critical to evaluating claim options and potential compensation timelines.
Table of Contents
- What Is BIA-ALCL and Why Did the FDA Recall Allergan Textured Implants?
- The Medical Evidence Linking Allergan Biocell Implants to BIA-ALCL
- The MDL-2921 Litigation Structure and Timeline
- Who Is Eligible to File a Claim, and What Information Is Needed?
- Settlement Status and Why No Global Settlement Has Been Reached Yet
- What the Expert Discovery Process Means for Your Case
- The October 2026 Bellwether Trial and Its Impact on the Broader Litigation
What Is BIA-ALCL and Why Did the FDA Recall Allergan Textured Implants?
BIA-ALCL is a rare form of non-Hodgkin’s lymphoma that develops in scar tissue surrounding a breast implant—not in the breast tissue itself. This distinction is important because many patients initially confuse it with breast cancer. BIA-ALCL is a malignant blood cancer affecting immune cells, and it occurs when abnormal T-cells accumulate in the capsule of scar tissue that naturally forms around an implant. The disease can take several years to develop after implantation, which is why women with older implants may only now be diagnosed. Symptoms often include persistent pain, swelling, fluid accumulation (seroma), or a mass near the implant site. Once identified, treatment typically requires explantation (surgical removal of the implant and surrounding scar tissue), sometimes followed by chemotherapy or radiation if the cancer has spread beyond the capsule.
In July 2019, the FDA requested Allergan’s recall of its Biocell textured breast implants after epidemiological data showed an unusually high rate of BIA-ALCL among women with these specific implants. The FDA did not ban all textured implants—only Allergan’s Biocell line. The recall affected approximately 210,000 implants worldwide. Unlike some product recalls, women were not automatically notified or advised to have implants removed unless they developed symptoms. This created a significant gap: many women with Allergan implants remained unaware of their elevated risk and continued living with implants that regulatory authorities had determined posed sufficient danger to warrant recall. Families have reported learning about the recall only after a woman presented to a hospital with symptoms of BIA-ALCL, leading to diagnosis that could potentially have been prevented with earlier awareness and prophylactic explantation.
The Medical Evidence Linking Allergan Biocell Implants to BIA-ALCL
The epidemiological link between textured breast implants and BIA-ALCL has been consistently documented. Studies show that BIA-ALCL is rare in women with smooth implants, but the incidence increases significantly with textured varieties—and is highest with Allergan’s Biocell design. The FDA’s own investigations and international health agencies found that the textured surface, which was marketed as providing better stability and lower rates of capsular contracture, may create an environment where chronic inflammation and bacterial biofilm formation occur around the implant. This inflammatory response over many years can potentially lead to malignant transformation of immune cells. One limitation plaintiffs face is that BIA-ALCL is still extremely rare in absolute terms.
The lifetime risk for a woman with Biocell implants is estimated at 1 in 1,000 to 1 in 3,000, which is why causation in individual cases requires careful medical and expert analysis. A woman diagnosed with BIA-ALCL must prove, through expert medical testimony, that her implants were the causative agent and not some other factor. This is particularly challenging in cases where a woman had implants for many years without developing the condition, or in cases where diagnosis occurred decades after implantation. Defense experts will argue that correlation alone does not establish that Allergan’s implants caused the disease in that specific plaintiff. The burden of proof is on the plaintiff’s legal team to establish medical causation through expert witnesses, which can be expensive and time-consuming—factors that have kept some potential claimants from pursuing litigation.
The MDL-2921 Litigation Structure and Timeline
In December 2019, shortly after the FDA recall, the Judicial Panel on Multidistrict Litigation established MDL-2921 in the U.S. District Court for the District of New Jersey, with Judge Brian Martinotti presiding. This litigation structure consolidates related cases for pretrial discovery and management, rather than litigating them individually across multiple districts. As of May 2025, 1,261 lawsuits with 1,425 plaintiffs are pending in the MDL. The consolidation allows for efficient sharing of expert reports, discovery documents, and pretrial motions while preserving each plaintiff’s individual claim and right to a trial. However, plaintiffs should understand that MDL status also means their case is not resolved—it sits in limbo during the discovery and expert phase, with no guaranteed settlement timeline.
The litigation has progressed through several key milestones. Discovery has included requests for Allergan’s internal documents, communications, marketing materials, and adverse event reports. Expert discovery—the phase in which both sides’ medical experts prepare detailed reports on causation, damages, and related issues—has an upcoming deadline of May 27, 2026. The first bellwether trial is scheduled for October 19, 2026, and will be a surgical explant trial focused on liability, meaning it will test whether a jury believes Allergan bears responsibility for the plaintiffs’ injuries. The outcome of this bellwether trial will likely influence settlement negotiations and future trial outcomes. Monthly case management conferences ensure the litigation maintains momentum, though no global settlement has been announced. Claimants in this MDL should prepare for potential continued litigation into 2027 and beyond unless a major settlement is reached.
Who Is Eligible to File a Claim, and What Information Is Needed?
To join the MDL-2921 litigation or file a claim related to Allergan Biocell implants, you must demonstrate that you received Allergan Biocell textured breast implants (identified by lot number or medical records) and that you have developed BIA-ALCL or another condition directly related to the implants. Medical documentation is critical: you will need records showing the brand and model of implants, the date of implantation, and a confirmed diagnosis of BIA-ALCL or related lymphoma. Some women with persistent implant-related complications, capsular contracture, or other inflammatory conditions are exploring claims, but the strongest cases to date involve documented BIA-ALCL diagnosis. Interestingly, if you had implants placed for breast reconstruction after cancer or injury, you may have additional claims under different legal theories than purely cosmetic implant recipients.
The process for filing typically involves contacting an attorney who handles MDL personal injury claims, providing your medical records and implant documentation, and allowing the attorney to evaluate whether your case meets the criteria for litigation. Unlike some class actions where a claim form and proof of purchase are sufficient, MDL cases require detailed medical causation analysis, which means you should expect an attorney to ask extensive questions about your medical history, symptoms, timeline, and any other potential causes of lymphoma. There is no central claims administrator collecting claimant information for Allergan implants as of 2026—each case is being pursued through individual representation. This means women injured by these implants must actively seek legal counsel rather than responding to a settlement notice. Be cautious of any online “claims” portals claiming to represent this litigation; verify directly with established personal injury law firms or medical device litigation specialists.
Settlement Status and Why No Global Settlement Has Been Reached Yet
As of early 2026, no finalized settlement agreement exists in MDL-2921, despite more than six years passing since the FDA recall. This is a critical point for claimants to understand: if you are waiting for an automatic settlement check or class action distribution, that is not imminent. Several factors explain the delay. First, the medical science around BIA-ALCL causation, while improved, is still developing. Defendants continue to challenge whether Allergan’s implants specifically cause BIA-ALCL or whether textured implants in general present the same risk. Second, the case involves questions about how many women were actually harmed and what compensation should be appropriate—these are disputed between plaintiffs and Allergan.
Third, Allergan (now part of AbbVie after a 2020 acquisition) has no incentive to settle without seeing how a bellwether jury decides the liability question. The absence of a settlement means each case remains in active litigation, with ongoing costs, expert fees, and uncertainty. For claimants, this creates both risk and potential upside. The risk is that a negative bellwether trial verdict could weaken remaining cases and reduce settlement use. The upside is that if liability is established and damages are awarded in the bellwether trial, Allergan may finally agree to a broader settlement to avoid years of additional individual trials. Claimants should not assume a settlement will arrive soon—instead, they should be prepared that litigation may continue into 2027 or 2028. Conversely, if you have a strong medical case, the lack of a global settlement means you retain the right to an individual trial and jury verdict, which could result in a larger award than a per-plaintiff settlement amount would provide.
What the Expert Discovery Process Means for Your Case
Expert discovery, with a May 27, 2026 deadline, is the phase in which medical experts on both sides prepare written reports detailing their opinions on causation, medical standards of care, and damages. These reports become key evidence in the litigation. Plaintiffs’ experts will opine that Allergan knew or should have known of the BIA-ALCL risk, failed to warn adequately, and that the implants directly caused the plaintiff’s lymphoma. Defense experts will argue that the risk was unknown, that many women with Biocell implants never develop BIA-ALCL, or that the diagnosis resulted from other factors. The expert reports, exchanged between attorneys and courts, become part of the trial record and can be devastating or protective depending on their conclusions.
For claimants, this phase matters because expert opinions influence settlement discussions and trial strategy. If your case has been selected for early evaluation or management by your attorney, you may be asked to provide detailed medical history, imaging records, and timeline information to support expert opinions. Some cases may be deemed unsuitable for litigation if experts conclude causation cannot be adequately proven, which could affect your claim’s value. Conversely, if experts strongly support causation in your case, it may be prioritized for settlement discussions or early trial. The expert discovery deadline of May 27, 2026 is a critical inflection point—after expert reports are exchanged, the litigation’s trajectory and settlement likelihood will become clearer.
The October 2026 Bellwether Trial and Its Impact on the Broader Litigation
The first bellwether trial, scheduled for October 19, 2026, will focus on surgical explant—meaning it will involve a plaintiff whose Allergan implants have been removed and analyzed, and who has undergone treatment for BIA-ALCL. This is the trial most likely to produce a clear liability verdict because it involves the most severe, fully documented injury. A win for plaintiffs in this trial could trigger rapid settlement negotiations and increased compensation offers. A verdict in Allergan’s favor could stall settlement discussions and lead to additional individual trials before any broader resolution.
The trial will be closely watched by all parties, and the outcome will directly affect how remaining cases are valued and whether claimants should pursue continued litigation or push for a settlement. Prior to the October trial, other bellwether cases may be selected for earlier trials or mediation sessions. The litigation is now in a phase where monthly status conferences maintain momentum, and attorneys on both sides are preparing for the real possibility of multiple jury trials. For claimants, the October 2026 bellwether trial represents the moment when Allergan’s liability will be tested in an actual courtroom, with a jury of ordinary people deciding whether the company should be held responsible for women’s injuries. This event will reshape the litigation’s trajectory and settlement landscape.
You Might Also Like
- StairMaster Peloton Tread Recall Safety Class Action
- Philips Respironics Ventilator Recall Death Class Action
- Abbott Baby Formula Contamination Recall Class Action
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: